Treatment of knee joint osteoarthritis with Glucosamine: aspects of pharmacokinetics (a literature review)

Roy D.Altman

Abstract


Knee joint osteoarthrosis is the commonest form of arthrosis. With regard for ageing of population in all countries it is prognosticated that the number of problems, caused by this disease, will significantly increase within the next few decades. As a medicinal drug for treating symptoms and preventing development of knee joint osteoarthrosis the studies involved Glucosamine, which demonstrated its symptomatic and modifying effects. Nevertheless the results of studies of the use of Glucosamine in gonarthrosis, made by today, turned out to be contradictory because of differences and/or shortcomings of models, numbers of observations, inadequacy in the composition of the studied drugs and their quality. The review provides the up-to-date level of information on pharmacokinetics of Glucosamine that may help in interpreting results of pharmacodynamics and clinical efficacy, received in different clinical studies.


Keywords


Glucosamine hydrochloride; Glucosamine sulfate; pharmacokinetics; knee joint osteoarthritis; treatment

References


Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee / R.D. Altman, E. Asch, D. Bloch et al. // Arthritis Rheum. — 1986. — Vol. 29(8). — P. 1039–1049.

Fox B.A. Glucosamine hydrochloride for the treatment of osteoarthritis ymptoms / B.A. Fox, M.M. Stephens // Clin. Interv. Aging. — 2007. — Vol. 2(4). — P. 599–604.

Felson D.T. Osteoarthritis of the knee / D.T. Felson // N. Engl. J. Med. — 2006. — Vol. 354(8). — P. 841–848.

Woolf A.D. Burden of major musculoskeletal conditions / A.D. Woolf, B. Pfleger // Bull. World Health Organ. — 2003. — Vol. 81(9). — P. 646–656.

Assessment of the Lequesne index of severity for osteoarthritis of the hip in an elderly population / J. Dawson, L. Linsell, H. Doll et al. // Osteoarthritis Cartilage. — 2005. — Vol. 13(10). — P. 854–860.

Hospital, pharmacy and outpatient costs for osteoarthritis and chronic back pain / D.W. Mapel, M. Shainline, K. Paes, M. Gunter // J. Rheumatol. — 2004. — Vol. 31(3). — P. 573–583.

Pain exacerbation as a major source of lost productive time in US workers with arthritis / J.A. Ricci, W.F. Stewart, E. Chee et al. // Arthritis Rheum. — 2005. — Vol. 53(5). — P. 673–681.

Editorial. Glucosamine therapy for osteoarthritis: an update / Т.Е. Towheed, T. Anastassiades // J. Rheumatol. — 2007. — Vol. 34(9). — P. 1787–1790.

Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial // J.Y. Reginster, R. Deroisy, L.C. Rovati et al. // Lancet. — 2001. — Vol. 357. — P. 251–256.

Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomised, placebo-controlled, doubleblind study / K. Pavelka, J. Gatterova, M. Olejarová et al. // Arch. Intern. Med. — 2002. — Vol. 162(18). — P. 2113–2123.

Glucosamine sulfate in the treatment of knee osteoarthritis symptoms. A randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator / G. Herrero-Beaumont, J.A.R. Ivorra, M.C. Trabado et al. // Arthritis Rheum. — 2007. — Vol. 56(2). — P. 555–567.

Vangsness C.T. A review of evidence-based medicine for glucosamine and chondroitin sulfate use in knee osteoarthritis / C.T. Vangsness, W. Spiker, J. Erickson // Arthroscopy. — 2009. — Vol. 25(1). — P. 86–94.

Reginster J.Y. Editorial. The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest / J.Y. Reginster // Arthritis Rheum. — 2007. — Vol. 56(7). — P. 2105–2110.

Setnikar I. Absorption, distribution, metabolism and excretion of glucosamine sulfate / I. Setnikar, L.C. Rovati // Arzneimittelforschung. — 2001. — Vol. 51(11). — P. 699–725.

Hamerman D. The biology of osteoarthritis / D. Hamerman // N. Engl. J. Med. — 1989. — Vol. 320(20). — P. 1322–1330.

Rodén L. Effects of hexosamines on the synthesis of chondroitin sulphuric acid in vitro / L. Rodén // Ark. Kemi. — 1956. — Vol. 10. — P. 345–352.

Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis / D.O. Clegg, D.J. Reda, C.L. Harris et al. // N. Engl. J. Med. — 2006. — Vol. 354(8). — P. 795–808.

Glucosamine therapy for treating osteoarthritis / Т.Е. Towheed, L. Maxwell, T.P. Anastassides et al. // Cochrane Database Syst. Rev. — 2005. — Vol. 18(2). — CD002946.

Dodge G.R., Jimenez S.A. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3-synthesized by cultured human osteoarthritis articular chondrocytes / G.R. Dodge, S.A. Jimenez // Osteoarthritis Cartilage. — 2003. — Vol. 11(6). — Vol. 424–432.

Use of 3H-glucosamine and 35S-sulfate with cultured human chondrocytes to determine the effect of glucosamine concentration on formation of chondroitin sulfate / P.J. Mroz, J.E. Silbert // Arthritis Rheum. — 2004. — Vol. 50(11). — P. 3574–3579.

Glucosamine modulates chondrocyte proliferation, matrix synthesis, and gene expression / S. Varghese, P. Theprungsirikul, S. Sahani et al. // Osteoarthritis Cartilage. — 2007. — Vol. 15(1). — P. 59–68.

Pelletier J.P. Rationale for the use of structure-modifying drugs and agents in the treatment of osteoarthritis / J.P. Pelletier // Osteoarthritis Cartilage. — 2004. — Vol. 12(Suppl. A). — P. 63–68.

Glucosamine inhibits IL-1-beta- induced NFkB activation in human osteoarthritic chondrocytes / R. Largo, M.A. Alvarez-Soria, I. Díez-Ortego et al. // Osteoarthritis Cartilage. — 2003. — Vol. 11(4). — P. 290–298.

Glucosamine sulfate inhibits IL-1-stimulated gene expression at concentrations found in humans after oral intake / T. Piepoli, T. Zanelli, O. Letari et al. // Arthritis Rheum. — 2005. — Vol. 9(Suppl.). — P. 1326.

Development and validation of a sensitive HPLC-ESI-MS/MS method for the direct determination of glucosamine in human plasma / A. Roda, L. Sabatini, A. Barbieri et al. // J. Chromatogr. — 2006. — Vol. 844(1). — P. 119–126.

Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man / S. Persiani, E. Roda, L.C. Rovati et al. // Osteoarthritis Cartilage. — 2005. — Vol. 13(12). — P. 1041–1049.

Synovial and plasma glucosamine concentration in osteoarthritic patients following oral crystalline glucosamine sulfate at therapeutic dose / S. Persiani, R. Rotini, G. Trisolino et al. // Osteoarthritis Cartilage. — 2007. — Vol. 15(7). — P. 764–772.

The pharmacokinetics of oral glucosamine and chondroitin sulfate in humans / C.G. Jackson, A.H. Plaas, J.G. Barnhill et al. // Arthritis Rheum. — 2005. — Vol. 52(9 Suppl). — L13.

The multiple-dose pharmacokinetics of orally administered glucosamine and chondroitin sulfate in humans. Presented at: ACR/ARHPAnnual Scientific Meeting / C.G. Jackson, A.H. Plaas, J.G. Barnhill et al. — Washington, DC, USA, 2006.

Pharmacokinetics of glucosamine in man after oral administration of crystalline glucosamine sulfate or glucosamine hydrochloride alone or in combination with chondroitin sulfate / S. Persiani, L.C. Rovati, E. Pastorini et al. // Osteoarthritis Cartilage. — 2007. — Vol. 15(Suppl.C). — C223.

Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride / M. Meulyzer, P. Vachon, F. Beaudry et al. // Osteoarthritis Cartilage. — 2008. — Vol. 16(9). — P. 973–979.

Evaluation of crystalline glucosamine sulfate plasma to blood partitioning and protein binding in human and mouse plasma and binding in human synovial fluid / S. Persiani, P. Larger, L. Canciani et al. // Drug Metab. Rev. — 2008. — Vol. 40(3). — P. 255.

Glucosamine does not inhibit or induce human cytochromes P450 / S. Persiani, L. Cancianji, W.L. Ricci et al. // Drug Metab. Rev. — 2006. — Vol. 38(2). — P. 255.

Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocationin skeletal muscle / A.D. Baron, J.S. Zhu, J.H. Zhu et al. // J. Clin. Invest. — 1995. — Vol. 6. — P. 2792–2801.

Shortterm glucosamine infusion does not affect insulin sensitivity in humans / M.J. Pouwels, J.R. Jacobs, P.N. Span et al. // J. Clin. Endocrinol. Metab. — 2001. — Vol. 86(5). — P. 2099–2103.

Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects / R. Muniyappa, R.J. Karne, G. Hall et al. // Diabetes. — 2006. — Vol. 55(11). — P. 3142–3150.

Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, 103rd Congress, 25 October, 1994.

Russell A.S. Active ingredient consistency of commercially available glucosamine sulfate products / A.S. Russell, A. Aghazadeh-Habashi, F. Jamali // J. Rheumatol. — 2002. — Vol. 29(11). — P. 2407–2409.

Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee / J.B. Houpt, R. McMillan, C. Wein, S.D. Paget-Dellio // J. Rheumatol. — 1999. — Vol. 26 (11). — P. 2423–2430.

Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee / J.P. Rindone, D. Hiller, E. Collacott et al. // West J. Med. — 2000. — Vol. 172 (2). — P. 91–94.

Hughes R. A randomised, double-blind, placebo-controlled trial of glucosamine sulfate as an analgesic in osteoarthritis of the knee / R. Hughes, A. Carr // Rheumatology. — 2002. — Vol. 41(3). — P. 279–284.

Randomised, double-blind, placebo- controlled glucosamine discontinuation trial in knee osteoarthritis / J. Cibere, J.A. Kopec, A. Thorne et al. // Arthritis Rheum. — 2004. — Vol. 51(5). — P. 738–745.

Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial / R.M. Rozendaal, B.W. Koes, J.V.M. Gerjo et al. // Ann. Intern. Med. — 2008. — Vol. 148. — P. 268–277.

McAlindon T. Why are clinical trials of glucosamine no longer uniformly positive? / T. McAlindon // Rheum. Dis. Clin. — 2003. — Vol. 29(4). — P. 789–801.

OARSI recommendations for the management of hip and knee osteoarthritis, part I: Critical appraisal of existing treatment guidelines and systematic review of current research evidence / W. Zhang, R.W. Moskowitz, G. Nuki et al. // Osteoarthritis Cartilage. — 2007. — Vol. 15. — P. 981–1000.

OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines / W. Zhang, R.W. Moskowitz, G. Nuki et al. // Osteoarthritis Cartilage. — 2008. — Vol. 16. — P. 137–162.




DOI: https://doi.org/10.15674/0030-598720121101-110

Refbacks

  • There are currently no refbacks.


Copyright (c) 2014 Roy D.Altman

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.